Coya Therapeutics, Inc. 8-K

What Happened

• Coya Therapeutics, Inc. announced results of operations for the fiscal quarter ended March 31, 2026 via a press release dated May 12, 2026 (furnished as Exhibit 99.1 to the Form 8‑K).
• Separately, on May 11, 2026 the U.S. Food and Drug Administration granted Fast Track Designation to COYA‑302 for the treatment of Amyotrophic Lateral Sclerosis (ALS). The Form 8‑K was signed by CEO Arun Swaminathan, Ph.D., on May 12, 2026.

Key Details

• Filing: Form 8‑K filed May 12, 2026 (Items 2.02 and 8.01).
• Press release: Dated May 12, 2026 and furnished as Exhibit 99.1 (discloses the company’s results for the quarter ended March 31, 2026).
• Regulatory: FDA Fast Track Designation granted for COYA‑302 for ALS on May 11, 2026.
• Officer: Report signed by Arun Swaminathan, Ph.D., Chief Executive Officer.

Why It Matters

• The Fast Track designation for COYA‑302 may allow Coya to have more frequent FDA interactions and potentially accelerate development and review timelines for its ALS program — a material regulatory development for a clinical‑stage asset.
• The company’s disclosed quarterly results (via the May 12 press release) are the primary source for investors to evaluate near‑term financial performance and operating trends; the Form 8‑K furnishes that press release but does not restate detailed financials in the body of the filing.
• Investors should review the Exhibit 99.1 press release and subsequent company updates for specific revenue, expense, cash‑balance or clinical program milestones that could affect valuation or near‑term catalysts.